Results 71 to 80 of about 231 (96)
Some of the next articles are maybe not open access.
Somatrogon in paediatric growth hormone deficiency: a profile of its use in the EU
Drugs and Therapy Perspectives, 2022Zaina T Al-Salama +2 more
exaly +2 more sources
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +2 more sources
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +2 more sources
Expert Review of Endocrinology & Metabolism, 2023
Somatrogon (NGENLA™) is a long-acting GH (LAGH) formulation that was approved in Canada in October 2021 for the treatment of pediatric growth hormone deficiency (GHD). Somatrogon has also received approval in Australia, Japan, the European Union, the USA, and the UK.
Eric P, Velazquez +2 more
openaire +2 more sources
Somatrogon (NGENLA™) is a long-acting GH (LAGH) formulation that was approved in Canada in October 2021 for the treatment of pediatric growth hormone deficiency (GHD). Somatrogon has also received approval in Australia, Japan, the European Union, the USA, and the UK.
Eric P, Velazquez +2 more
openaire +2 more sources